^
    Back
    Association details:
    Biomarker:PRAME expression
    Cancer:Ovarian Cancer
    Drug:brenetafusp (IMC-F106C) (CD3 agonist, PRAME inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    AACR 2020
    Title:

    Abstract 5572: IMC-F106C, a novel and potent immunotherapy approach to treat PRAME expressing solid and hematologic tumors

    Published date:
    05/15/2020
    Excerpt:
    In the PRAME positive HLA-A*02:01 positive cell lines, IMC-F106C redirected donor effector cells to release IFNγ and GrB and kill tumor cells in a dose-dependent manner, with activity demonstrated as low as < 1 pM. By contrast, cell lines negative for PRAME or HLA-A*02:01 expression failed to induce responses < 1 nM of IMC-F106C.
    DOI:
    10.1158/1538-7445.AM2020-5572